US Transdermal Patch Clinical Pipeline Insight by Company, Indication and Phase
Number of Patch In Clinical Trials: > 40 Patch
Availability, Dosage and Price Analysis On 20 Patches Approved by FDA
Marketed Transdermal Patch Clinical Insight: > 25 FDA Approved Patch
Value Chain Analysis for US Transdermal Patch Market
US Transdermal Patch Market Opportunity Assessment by Indication
Transdermal patch market consists of a non invasive method of introducing desirable drug into the body of the patient. In past few years, this respective mode of drug delivery which is painless and non-invasive has become one of the most attractive mode of drug delivery. The same has also been classified as one of the most innovative and classic therapeutics sectors in the entire pharmaceutical market. Drug delivery market is packed with tons of application-based methods of delivering desired drug into the patients, but the total appreciation and adoption rate received by transdermal patch from the researchers and the patients have conventionally transformed the entire market into one of the most desirable therapeutics market with a market size worth billions of dollars.
"US Transdermal Patch Market Opportunity Will Surpass USD 6 Billion In Next Few Years Driven By Technology Innovation And Increasing Acceptability Toward Patch Drug Delivery Methodology"
Only transdermal patch drug delivery market is classified as one of the most pivotal contribution to the general pharmaceutical market as the market consists of attaching a patch to the desired part of the body, letting the drug to release inside the body in a controlled manner. Therefore, it can be recorded that the therapy in an indirect way has also been responsible for boosting the controlled drug delivery market trends and opportunities. The US transdermal patch drug delivery market is also associated with large number of major key players inclined towards developing transdermal patches for different diseases. In addition, continuous research and development strategies opted by the focused researchers towards adding novel techniques to it is also believed to be adding prominent drivers to the market.
"More Than 25 FDA Approved Patches Are Available In The US Market And More Than 40 Are In Clinical Trials"
There are numerous advantages that are observed within the therapy. Some of the application-based advantages associated with the therapy are: painless, non-invasive, convenient, release of desirable disease and many more. The ultimate exposure of the drug through transdermal patches is also leading to high rate of consumption of the drugs as well as extensive survival rate of the patients suffering from different types of diseases. The respective market for drug delivery is also witnessed to be dominating the other drug delivery markets that are present in the pharmaceutical industry for long period of time.
As per "US Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2026" report findings, it is estimated that for more than two or three decades from now, the respective market in the US will continue to dominate the entire pharmaceutical market in the world. Looking forward, the robust and strong clinical pipeline associated with the market at pre-clinical and clinical level for different diseases such as cancer and many more are estimated to yield more specific trends that are never observed in the pharmaceutical market at global level. The entire navigation of the US researchers towards the urgent need of an efficient drug delivery system and having a prominent non-invasive technique for eradicating the disease-causing cells from the body of the patient. As per the analysis done for the US transdermal patch market, it is believed that in the next few years, the US market will be identifying several drugs for different diseases that could be administered inside the body with the aid of transdermal patches, compared with early 2000’s.
Introduction to Transdermal Patch
Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
Why There Exist Need for Transdermal Patches?
Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine and Female Contraceptive Transdermal
Patch
Transdermal Patch v/s Traditional Drug Delivery Methods
US Transdermal Patch Market Overview
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview
6.2.1 By Company
6.2.2 By Drug Class
6.2.3 By Indication
6.2.4 By Phase
Generic and Branded Transdermal Patches
Value Chain Analysis for Transdermal Patch Market
8.1 Research and Development
8.2 Manufacturing
8.3 Marketing and Distribution
8.4 Price to End User
US Transdermal Patch Contract Manufacturing Organization (CMO)
Transdermal Patches for Cardiovascular Diseases - US Market Availability, Dosage and Price Analysis
10.1 Clonidine Transdermal Patch (Catapres–TTS)
10.2 Nitro Glycerin Transdermal Patch
10.2.1 Nitro-Dur
10.2.2 Nitro TD Patch A
10.2.3 Generic Nitroglycerine Trandsdermal Patch
Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage and Price Analysis
Figure 12-22: Global – Neupro Sales by Region (US$ Million), 2020
Figure 12-23: Global – Neupro Sales by Region (US$ Million), 2020
Figure 13-1: Alora – FDA Approval Year by Dose
Figure 13-2: Alora – Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg and 0.1mg (US$), March’2021
Figure 13-3: Alora – Price per Unit of 0.025mg, 0.05mg, 0.075mg and 0.1mg Transdermal Patch(US$), March’2021
Figure 13-4: Alora – Recommended Dose for Treatment of vaginal Atrophy and Postmenopausal Osteoporosis (mg/Day Twice in a Week), March’2021
Figure 13-5: Vivelle-Dot – FDA Approval and First Generic Approval Year
Figure 13-6: Vivelle-Dot - Price for a Supply of 24 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg and 0.1mg (US$), March’2021
Figure 13-7: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg and 0.1mg Transdermal Patch (US$), March’2021
Figure 13-8: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, and Postmenopausal Osteoporosis (mg/Day Twice a Week), March’2021
Figure 13-9: Minivelle – FDA Approval Year by Dose
Figure 13-10: Minivelle – FDA Approval and First Generic Approval Year
Figure 13-11: US – Minivelle Patent Issue and Expiration Year
Figure 13-12: Minnivelle – Price for a Supply of 8 Patches and Price Per Unit of Various Doses (US$), March’2021
Figure 13-13: Minivelle - Recommended Dose by Indication (mg/Day), March’2021
Figure 13-14: Climara – FDA Approval Year by Dose
Figure 13-15: Climara – FDA Approval and First Generic Approval Year
Figure 13-16: Climara – Average Price for a Supply of 4 Transdermal Films and Price Per Unit of Various Doses (US$), March’2021
Figure 13-17: Generic Estradiol Transdermal Patch – Price for 4 Films Supply and Price Per Unit of 0.025mg Film (US$), March’2021
Figure 13-18: Generic Estradiol Transdermal Patch – Price for 4 Films Supply and Price Per Unit of 0.0375mg Film (US$), March’2021
Figure 13-19: Generic Estradiol Transdermal Patch – Price for 4 Films Supply and Price Per Unit of 0.05mg and 0.06mg Dose (US$), March’2021
Figure 13-20: Generic Estradiol Transdermal Patch – Price for 4 Films Supply and Price Per Unit of 0.075mg Film (US$), March’2021
Figure 13-21: Generic Estradiol Transdermal Patch – Price for 4 Films Supply and Price Per Unit of 0.1mg Film (US$), March’2021
Figure 13-22: Androderm – Price for 60 Films Supply and per Unit Price of 2mg Transdermal Films (US$), March’2021
Figure 13-23: Androderm – Price for 30 patch Supply and per Unit Price of 4mg Transdermal Patch (US$), March’2021
Figure 13-24: Androderm – Recommended Initial and Maintainence Dose fot Treatment of Hypogonadism (mg/day), March’2021
Figure 13-25: Ortho Evara – FDA approval and Withdrawal Year
Figure 13-26: Xulane – FDA Approval and First Generic Approval Year
Figure 13-27: Xulane – Price for a Supply of 3 Patches and Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), March’2021
Figure 13-28: Xulane – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 13-29: CombiPatch – Price for a Supply of 8 Patches and Price Per Unit of Various Doses (US$), March’2021
Figure 13-30: Climara Pro – Price for a Supply of 4 Films and Price Per Unit of Transdermal Film (US$), March’2021
Figure 13-31: US – Twirla Patent Issue and Expiration Year
Figure 13-32: Twirla – Price for a Supply of 3 Patches and Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), March’2021
Figure 13-33: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 14-1: Nicotine Transdermal Patch – FDA Approval Year by Product
Figure 14-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), March’2021
Figure 14-3: Nicoderm CQ – Price per Unit of 7mg, 14mg and 21mg Transdermal Patch (US$), March’2021
Figure 14-4: Harbitrol – Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), March’2021
Figure 14-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), March’2021
Figure 14-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), March’2021
Figure 14-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg and 21mg (US$), March’2021
Figure 14-8: Nicoderm CQ – Recommended Dose and Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 14-9: Nicoderm CQ – Recommended Dose and Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 14-10: Nicoderm CQ – Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes and More than 10 Cigarettes (US$), March’2021
Figure 14-11: Oxytrol – Price of 8 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-12: Oxytrol For Women – Price of 4 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-13: Oxytrol For Women – Price of 8 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-14: Sancuso – Patent Issue and Expiration Year
Figure 17-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 17-2: US - Susceptibility of Parkinson Disease Among Males and Females
Figure 17-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 17-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 17-5: US - Parkinson’s Disease Incidences, 2020-2026
Figure 17-6: US - Estimated Sales of Neupro Patch (US$ Million), 2020-2026
Figure 17-7: US - Male and Female Suffering from Alzheimer’s Disease (Million), 2021
Figure 17-8: US - Shares of Male and Female Suffering from Alzheimer’s Disease (%), 2021
Figure 17-9: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2021
Figure 17-10: US - Estimated Increase in Alzheimer’s Incidences (Million), 2020, 2030, 2040 and 2050
Figure 17-11: US - Estimated Incidences of Alzheimer’s Disease, 2021-2026
Figure 17-12: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 17-13: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 17-14: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 and 2019
Figure 17-15: US – Prevalence of Smokers by Gender (%), 2019
Figure 17-16: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 17-17: US – Estimated Cases of Adult Hypertension (Million), 2019, 2025 and 2030
Figure 17-18: US – Adult Hypertension Cases by Gender (Million), 2019
Figure 17-19: US – Adult Hypertension Cases by Gender (Million), 2019
Figure 17-20: US – Adult Hypertension Cases by Age (Million), 2019
Figure 17-21: US – Hypertension Prevalence Rate by Age (%), 2019
Figure 17-22: US - Hypertension Incidences (Million), 2020-2026
Figure 17-23: Rank of US among Different Diabetes Prone Countries
Figure 17-24: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 and 2045
Figure 17-25: US – Undiagnosed and Diagnosed Diabetic Population (Million), 2019
Figure 17-26: US – Undiagnosed and Diagnosed Diabetic Population (%), 2019
Figure 17-27: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 and 2045
Figure 17-28: US – Estimated Diabetic Population (Million), 2020-2026
Figure 17-29: Benefits of Insulin Transdermal Patch
Figure 17-30: Drawback of Insulin Transdermal Patch
Figure 17-31: Benefits of Vaccine Transdermal Patch
Figure 17-32: Drawbacks of Vaccine Transdermal Patch
Figure 17-33: US – Number of HIV Cases (Million), 2012, 2014 and 2018
Figure 17-34: US – Estimated Number of HIV Cases (Million), 2020, 2025 and 2030
Figure 17-35: US - Estimated HIV Incidences, 2020-2026
